NCT03397641View on ClinicalTrials.gov

A Phase 1 Study of HBI-3000

PHASE1CompletedINTERVENTIONAL

Enrollment

47

Participants

Timeline

Start Date

October 17, 2017

Primary Completion Date

July 10, 2018

Study Completion Date

July 10, 2018

Conditions

Atrial Fibrillation

Interventions

DRUG

HBI-3000

Small molecule, multi-ion channel blocker

OTHER

Placebo

Normal Saline

Trial Locations (1)

NG11 6JS

Quotient Clinical, Nottingham

Sponsors

Collaborators (1)

Quotient Clinical

All Listed Sponsors

collaborator

Quotient Clinical

OTHER

lead

HUYABIO International, LLC.

INDUSTRY

NCT03397641 - A Phase 1 Study of HBI-3000 | Biotech Hunter | Biotech Hunter